Want to see HK:2137 full AI Analyst Report?

Brii Biosciences Limited (2137) Price & Analysis

2 Followers

2137 Stock Chart & Stats

HK$1.44

HK$0.04(3.74%)

At close: Jan 09 4:00 PM EST

HK$1.44

HK$0.04(3.74%)

Day’s Range― - ―

52-Week RangeHK$0.90 - HK$2.54

Previous CloseN/A

Volume2.92M

Average Volume (3M)6.36M

Market Cap

HK$678.54M

Enterprise Value-HK$1.19K

Total Cash (Recent Filing)HK$1.94B

Total Debt (Recent Filing)HK$8.93M

Price to Earnings (P/E)―

Beta1.45

Next Earnings

Aug 20, 2026

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding734,577,100

10 Day Avg. Volume5,897,564

30 Day Avg. Volume6,360,478

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)0.38

Price to Sales (P/S)50.44

P/FCF Ratio-3.17

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.43

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetThe company’s very low leverage and positive equity through 2021–2025 materially lower refinancing and solvency risk, giving management flexibility to fund clinical programs and commercialization activities. This balance-sheet strength supports multi-quarter R&D investment without forced asset sales.

Reduced Losses And Cash Burn In 2025Reported improvement in 2025 losses and reduced cash burn versus 2024 indicates traction toward stabilizing cash requirements. If sustained, this trend can extend runway and reduce near-term external financing need, enabling continuity in trials and incremental commercialization investment over months.

Focused Infectious-disease PipelineA focused pipeline on infectious diseases and stated commercialization capabilities is a structural asset: it concentrates expertise, regulatory experience and go-to-market setup, improving probability of commercial launches and partner interest across public-health markets over the medium term.

Bears Say

Persistent Negative Operating & Free Cash FlowOngoing negative operating and free cash flow means the business continues to consume liquidity to fund operations. Persistent cash burn raises dependence on external financing, heightens dilution or debt risk, and constrains discretionary R&D or commercial scale-up without capital infusions.

Consistent Net Losses And Negative MarginsConsistent net losses and deeply negative margins across years show the company has not yet achieved unit economics or scalability. Negative profitability limits internal capital generation, pressures returns on invested capital, and prolongs reliance on funding to reach sustainable margins.

Sharp Revenue Contraction In 2025A material revenue contraction in 2025 versus 2024 signals weaker commercial traction or lower demand for existing products. Declining top-line hampers scale economies, makes R&D funding more urgent, and may delay breakeven timelines absent new approvals or partnership revenue.

Brii Biosciences Limited News

Brii Biosciences Posts Promising Phase 2b Hepatitis B Data but Elebsiran Future Clouded by Arbitration

Brii Biosciences Limited ( ($HK:2137) ) just unveiled an announcement. Brii Biosciences has reported end-of-treatment data from its...

1M ago

Brii Biosciences Launches HK$60 Million Share Buy-back to Signal Confidence and Unlock Value

Brii Biosciences Limited ( ($HK:2137) ) has provided an announcement. Brii Biosciences Limited has announced that its board...

2M ago

Brii Biosciences Shareholders Approve All Resolutions at 2026 AGM

Brii Biosciences Limited ( ($HK:2137) ) has shared an announcement. Brii Biosciences reported that all resolutions proposed at...

2M ago

Brii Biosciences Warns Hepatitis B Drug Program at Risk Amid Vir Arbitration

Brii Biosciences Limited ( ($HK:2137) ) has provided an update. Brii Biosciences has disclosed that its ongoing arbitration...

3M ago

Brii Biosciences Data Backs Shorter NRTI Use in Next-Generation HBV Therapies

An announcement from Brii Biosciences Limited ( ($HK:2137) ) is now available. Brii Biosciences has presented new data...

3M ago

Brii Biosciences Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority

Brii Biosciences Limited ( ($HK:2137) ) has shared an update. Brii Biosciences Limited has called its annual general...

3M ago

Brii Biosciences Launches Arbitration Against Vir Over Hepatitis B Drug Manufacturing Rights

The latest announcement is out from Brii Biosciences Limited ( ($HK:2137) ). Brii Biosciences has initiated arbitration proceedings...

4M ago

Brii Biosciences Narrows 2025 Loss as Costs Fall and Revenue Emerges

An announcement from Brii Biosciences Limited ( ($HK:2137) ) is now available. Brii Biosciences reported its annual results...

5M ago

Brii Biosciences Confirms 2025 PFIC Status, Issues Tax Statement for U.S. Holders

An update from Brii Biosciences Limited ( ($HK:2137) ) is now available. Brii Biosciences Limited has notified its...

5M ago

Brii Biosciences Sets March 2026 Board Meeting to Approve 2025 Annual Results

Brii Biosciences Limited ( ($HK:2137) ) has issued an update. Brii Biosciences Limited has scheduled a board meeting...

5M ago

2137 FAQ

What was Brii Biosciences Limited’s price range in the past 12 months?

Brii Biosciences Limited lowest stock price was HK$0.90 and its highest was HK$2.54 in the past 12 months.

What is Brii Biosciences Limited’s market cap?

Brii Biosciences Limited’s market cap is HK$678.54M.

When is Brii Biosciences Limited’s upcoming earnings report date?

Brii Biosciences Limited’s upcoming earnings report date is Aug 20, 2026 which is in 14 days.

How were Brii Biosciences Limited’s earnings last quarter?

Brii Biosciences Limited released its earnings results on Mar 19, 2026. The company reported -HK$0.035 earnings per share for the quarter, beating the consensus estimate of -HK$0.07 by HK$0.035.

Is Brii Biosciences Limited overvalued?

According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brii Biosciences Limited pay dividends?

Brii Biosciences Limited does not currently pay dividends.

What is Brii Biosciences Limited’s EPS estimate?

Brii Biosciences Limited’s EPS estimate is -0.13.

How many shares outstanding does Brii Biosciences Limited have?

Brii Biosciences Limited has 734,577,100 shares outstanding.

What happened to Brii Biosciences Limited’s price movement after its last earnings report?

Brii Biosciences Limited reported an EPS of -HK$0.035 in its last earnings report, beating expectations of -HK$0.07. Following the earnings report the stock price went down -3.947%.

Which hedge fund is a major shareholder of Brii Biosciences Limited?

Currently, no hedge funds are holding shares in HK:2137

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Brii Biosciences Limited

Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.